Ratio of Infections to COVID-19 Cases and Hospitalizations in the United States based on SARS-CoV-2 Seroprevalence Data, September 2021-February 2022

被引:0
|
作者
Deng, Yangyang [1 ]
Kim, Yun [1 ]
Bratcher, Anna [2 ]
Jones, Jefferson M. [3 ]
Simuzingili, Muloongo [3 ]
Gundlapalli, Adi, V [3 ]
Hagen, Melissa Briggs [3 ]
Iachan, Ronaldo [1 ]
Clarke, Kristie E. N. [3 ]
机构
[1] ICF Macro Inc, Reston, VA USA
[2] CDC, Epidem Intelligence Serv, Atlanta, GA USA
[3] CDCP, COVID 19 Response Team, Atlanta, GA USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2025年 / 12卷 / 01期
关键词
antibody; COVID-19; immunology; SARS-CoV-2; seroprevalence; OMICRON VARIANT;
D O I
10.1093/ofid/ofae719
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Understanding the risk of hospitalization from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections can guide effective public health interventions and severity assessments. This study calculated infection-hospitalization ratios (IHRs) and infection-case ratios (ICRs) to understand the relationship between SARS-CoV-2 infections, cases, and hospitalizations among different age groups during periods of Delta and Omicron variant predominance. Methods After calculating antinucleocapsid SARS-CoV-2 antibody seroprevalence using residual commercial laboratory serum specimens, 2 ratios were computed: (1) IHRs using coronavirus disease 2019 hospitalization data and (2) ICRs using Centers for Disease Control and Prevention surveillance data. Ratios were calculated across age groups (0-17, 18-49, 50-69, and >= 70 years) for 2 time periods (September-December 2021 [Delta] and December 2021-February 2022 [Omicron]). Results Pediatric IHRs increased from 76.7 during Delta to 258.4 during Omicron. Adult IHRs ranged from 3.0 (>= 70 years) to 21.6 (18-49 years) during Delta and from 10.0 (>= 70 years) to 119.1 (18-49 years) during Omicron. The pediatric ICR was lower during the Delta period (2.7) compared with the Omicron period (3.7). Adult ICRs (Delta: 1.1 [18-49 years] to 2.1 [70+ years]; Omicron: 2.2 [>70+ years] to 2.9 [50-69 years]) were lower than pediatric ICRs during both time periods. Conclusions All age groups exhibited a lower proportion of infections associated with hospitalization in the Omicron period than the Delta period; the proportion of infections associated with hospitalization increased with each older age group. A lower proportion of SARS-CoV-2 infections were associated with reported cases in the Omicron period than in the Delta period among all age groups.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States
    Turbyfill, Caitlin
    Adams, Katherine
    Tenforde, Mark W.
    Murray, Nancy L.
    Gaglani, Manjusha
    Ginde, Adit A.
    McNeal, Tresa
    Ghamande, Shekhar
    Douin, David J.
    Talbot, H. Keipp
    Casey, Jonathan D.
    Mohr, Nicholas M.
    Zepeski, Anne
    Shapiro, Nathan I.
    Gibbs, Kevin W.
    Files, D. Clark
    Hager, David N.
    Shehu, Arber
    Prekker, Matthew E.
    Frosch, Anne E.
    Exline, Matthew C.
    Gong, Michelle N.
    Mohamed, Amira
    Johnson, Nicholas J.
    Srinivasan, Vasisht
    Steingrub, Jay S.
    Peltan, Ithan D.
    Brown, Samuel M.
    Martin, Emily T.
    Lauring, Adam S.
    Khan, Akram
    Busse, Laurence W.
    Lohuis, Caitlin C. ten
    Duggal, Abhijit
    Wilson, Jennifer G.
    Gordon, Alexandra June
    Qadir, Nida
    Chang, Steven Y.
    Mallow, Christopher
    Rivas, Carolina
    Kwon, Jennie H.
    Halasa, Natasha
    Chappell, James D.
    Grijalva, Carlos G.
    Rice, Todd W.
    Stubblefield, William B.
    Baughman, Adrienne
    Rhoads, Jillian P.
    Lindsell, Christopher J.
    Hart, Kimberly W.
    VACCINE, 2022, 40 (48) : 6979 - 6986
  • [42] Genetic characteristics of SARS-CoV-2 virus variants observed upon three waves of the COVID-19 pandemic in Ukraine between February 2021-January 2022
    V. Gerashchenko, Ganna
    V. Hryshchenko, Nataliya
    Melnichuk, Nataliia S.
    V. Marchyshak, Tetiana
    Chernushyn, Serhii Yu
    V. Demchyshina, Irina
    Chernenko, Ludmyla M.
    V. Kuzin, Igor
    Tkachuk, Zenovii Yu
    Kashuba, Vladimir I.
    Tukalo, Mykhailo A.
    HELIYON, 2024, 10 (04)
  • [43] SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India
    Chunchu, Srinivasa Rao
    Ravula, Ushasree
    Gente, Vikram Kumar
    Bacchu, Srinivas
    Rao, S. Pandu Ranga
    Mooli, Srujaleswari
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (03) : 546 - 555
  • [44] Seroprevalence of SARS-CoV-2 among high-density communities and hyper-endemicity of COVID-19 in Vietnam
    Van Thuan Hoang
    Thi Dung Pham
    Quoc Tien Nguyen
    Duy Cuong Nguyen
    Duc Thanh Nguyen
    Thanh Binh Nguyen
    Thi Khanh Thu Tran
    Trong Lan Phan
    Phan Le Nguyen Vo
    Thi Loi Dao
    Fenollar, Florence
    Gautret, Philippe
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2022, 27 (05) : 515 - 521
  • [45] Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak
    Lombardi, Francesca
    Ricci, Rosalba
    Belmonti, Simone
    Fabbiani, Massimiliano
    Borghetti, Alberto
    Baldin, Gianmaria
    Ciccullo, Arturo
    Tamburrini, Enrica
    Visconti, Elena
    Sanguinetti, Maurizio
    Di Giambenedetto, Simona
    DIAGNOSTICS, 2021, 11 (07)
  • [46] Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States
    Muehleman, Deanna
    Gruner, Bill
    Hogan, Vivian
    Fanning, Padraic
    Garrett, Carol
    Meyer, Jennifer
    Lanter, Kelsey
    Purves, Sarah
    Demarcus, Laurie
    Thervil, Jeffrey
    Kwaah, Bismark
    Sjoberg, Paul
    Macias, Elizabeth
    Fries, Anthony
    EMERGING INFECTIOUS DISEASES, 2024, 30 (14) : 53 - 61
  • [47] Effectiveness of mRNA COVID-19 Vaccines and Hybrid Immunity in Preventing SARS-CoV-2 Infection and Symptomatic COVID-19 Among Adults in the United States
    Feldstein, Leora R.
    Ruffin, Jasmine
    Wiegand, Ryan E.
    Borkowf, Craig B.
    James-Gist, Jade
    Babu, Tara M.
    Briggs-Hagen, Melissa
    Chappell, James
    Chu, Helen Y.
    Englund, Janet A.
    Kuntz, Jennifer L.
    Lauring, Adam S.
    Lo, Natalie
    Carone, Marco
    Lockwood, Christina
    Martin, Emily T.
    Midgley, Claire M.
    Monto, Arnold S.
    Naleway, Allison L.
    Ogilvie, Tara
    Saydah, Sharon
    Schmidt, Mark A.
    Schmitz, Jonathan E.
    Smith, Ning
    Sohn, Ine
    Starita, Lea
    Talbot, H. Keipp
    Weil, Ana A.
    Grijalva, Carlos G.
    JOURNAL OF INFECTIOUS DISEASES, 2025, : e743 - e753
  • [48] Evaluation of COVID-19 Diagnosis Codes for Identification of SARS-CoV-2 Infections in a Nursing Home Cohort, 2022-2023
    Patel, Arshiya
    Payne, Amanda B.
    Currie, Dustin W.
    Franceschini, Thomas
    Gensheimer, Amber
    Lutgring, Joseph D.
    Reddy, Sujan C.
    Hatfield, Kelly M.
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2025, 26 (03)
  • [49] Trends in seroprevalence of SARS-CoV-2 in the Norwegian population through the first year of the COVID-19 pandemic
    Tunheim, Gro
    Ro, Gunnar Oyvind Isaksson
    Trung Tran
    Kran, Anne-Marte Bakken
    Andersen, Jan Terje
    Vaage, Eline Benno
    Kolderup, Anette
    Vaage, John Torgils
    Lundjohansen, Fridtjof
    Hungnes, Olav
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 344 - 344
  • [50] Initial determination of COVID-19 seroprevalence among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total antibody ELISA
    Thomas, Stefani N.
    Altawallbeh, Ghaith
    Zaun, Christopher P.
    Pape, Kathryn A.
    Peters, Jennifer M.
    Titcombe, Philip J.
    Dileepan, Thamotharampillai
    Rapp, Michael J.
    Bold, Tyler D.
    Schacker, Timothy W.
    Arbefeville, Sophie
    Ferrieri, Patricia
    Thyagarajan, Bharat
    Jenkins, Marc K.
    Karger, Amy B.
    CLINICAL BIOCHEMISTRY, 2021, 90 : 15 - 22